Rare Disease Data Center
Accelerating Biomedical Research with an AI-Powered Database of Disease Genes, Mutations, and Animal Models.
Unlocking the Secrets of Life with Large-scale Data
Your Research Assistant
Our Rare Disease Data Center (RDDC), supported by Research Institute of Tsinghua, Pearl River Delta (RITPRD) and Cyagen, comprehensively integrates authoritative information from numerous internationally renowned databases, aiding in rare disease research.
Effortlessly Master Rare Disease Knowledge with Advanced Data Visualization
The RDDC, created by RITPRD, is a database that combines open-source information on epidemiology, drug development, disease-related genes, gene mutations, and mouse models from both domestic and international sources.
Using genetic big data with AI and bioinformatics technology, RDDC offers AI tools like Pathogenicity Predictor and RNA Splicer, aiming to significantly advance research on rare diseases.
Timely Updated
The database is regularly updated to ensure accuracy and timeliness.
Data Visualization
Large-scale data is transformed into visual images to facilitate the observation of connections and trends.
Data Simplification
Large datasets are condensed and key information is highlighted for easier analysis.
All-in-One Access
Easily find data on rare diseases, genes, and animal models all in one place.
AI and Bioinformatics: A Powerful Alliance
Supporting Scientific Research Like Never Before
News and Updates
Corneal neovascularization (CNV) is a common clinical finding seen in a range of eye diseases. Current therapeutic approaches to treat corneal angiogenesis, in which vascular endothelial growth factor (VEGF) A plays a central role, can cause a variety of adverse side effects. The technology of Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/Cas9 can edit VEGFA gene to suppress its expression. CRISPR offers a novel opportunity to treat CNV.
Human cellular models of neurodegeneration require reproducibility and longevity, which is
There has been new progress in the research of Amyotrophic Lateral Sclerosis (ALS), with the discovery of a novel pathogenic gene—PCDHA9. Mouse animal models have confirmed that mutations at this pathogenic site can lead to a typical ALS phenotype, and an in-depth analysis of the pathogenic mechanism has been conducted.
Today (January 25th), the Eye, Ear, Nose, and Throat Hospital affiliated with Fudan University took
